The global preimplantation genetic testing (PGS/PGD) market size is projected to expand at a significant CAGR during the forecast period, 2021 – 2028. The growth of the market is attributed to the wide adoption of the in-vitro fertilization (IVF) procedure and the rapid use of preimplantation genetic diagnosis (PGD). These methods are beneficial in various ways that they allow the development of a healthy fetus while avoiding the possibility of selective pregnancy termination.
Wide adoption of preimplantation testing and screening processes can be primarily due to an increase in the occurrence of single gene, mitochondrial, and other gene-related disorders among a large number of population worldwide. According to the Florida Department of Health, about one out of every 28 babies in the state is diagnosed with a birth defect each year. For a healthy pregnancy, the PGD is used prior to decision for IVF. However, PGD is widely used in IVF procedures for women who have had multiple miscarriages or who have had a previous pregnancy with a chromosome abnormality. Early identification of congenital diseases in the early stages of the IVF workflow reduces the risk of hereditary chromosomal anomalies in the fetus over time. This present a key aspect of the market development.
Market Trends, Drivers, Restraints, and Opportunities
• Increasing occurrence of genetic disorder after the birth and wide prevalence of other gene-related disorders during pregnancy are expected to boost market growth.
• Advancement in innovative technology for genetic diagnosis such as the introduction of PGT monogenic disease diagnosis (PGT-M) is expected to spur the market development.
• Rising number of favorable government policies to promote awareness campaign about several pregnancy-related disorder and increasing development for healthy reproductive process are driving the market expansion. For example, the Swiss government approved the pre-implantation genetic diagnosis of an in-vitro embryo in June 2017.
• Social dogma and legal complexities associated with the identifying and mitigating genetic abnormalities in embryos prior to implantation are key challenges that can hamper the market growth.
• Growing understanding of fetus health among married couples as well as expanding applications of PGD and preimplantation genetic screening (PGS) are projected to boost market growth.
Market Segment Insights
PGD segment is expected to hold a dominant market share
Based on techniques, the global preimplantation genetic testing (PGS/PGD) market is bifurcated into PGS and PGD. The PGD segment is expected to hold a dominant market share in the coming years owing to increase knowledge among healthcare professionals and consumers about genetic testing of a particular gene mutation. Moreover, the segment growth is attributed to the rising occurrence of single gene diseases and translocation event, as well as market entities' successful delivery of NGS technology for genetic testing.
Aneuploidy screening segment is projected to register a high CAGR
On the basis of types, the market is divided into embryo testing, aneuploidy screening, chromosomal abnormalities, X-linked diseases, HLA typing, and other PGT types. The embryo testing segment is further classified as fresh embryo (own eggs), frozen embryo (own eggs), fresh embryo (donor eggs), and frozen embryo (donor eggs). In terms of revenue generation, the embryo testing segment held a major share of the market in 2018 due to wide PGT implementation for detecting chromosomal anomalies.
HLA typing for stem cell therapy segment to exhibit rapid growth
Based on applications, the global preimplantation genetic testing (PGS/PGD) market is divided into embryo HLA typing for stem cell therapy, IVF prognosis, late onset genetic disorders, inherited genetic disease, and others. The HLA typing for stem cell therapy segment to exhibit rapid growth owing to wide demand for preimplantation genetic testing in embryo HLA typing for stem cell therapy.
Asia Pacific is a fast-growing market
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Europe led the preimplantation genetic testing market in terms of revenue share in 2020 owing to a higher acceptance of IVF procedures due to a large number of late pregnancies cases. Furthermore, the market growth is bolstered by liberal aneuploidy screening legislation.
Some of the key players operating in the market are Illumina Inc.; Thermo Fisher Scientific, Inc.; Natera, Inc.; Bioarray S.L.; Good Start Genetics, Inc.; Laboratory Corporation of America Holdings; California Pacific Medical Center; Quest Diagnostics Incorporated; Reproductive Health Science Ltd.; CooperSurgical, Inc.; Genea Limited; IGENOMIX; Reproductive Genetic Innovations, LLC; F. Hoffmann-La Roche AG; and CombiMatrix. The market share of key players in genetic diagnosis that integrate continuous advances for effective implementation of PGT and screening have increased significantly. Several strategic steps are taken by key players including regional extensions, joint developments, and new product growth.
About Growth Market Reports:
GROWTH MARKET REPORTS provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Industry Intelligence Solutions”. GROWTH MARKET REPORTS has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Our key analysis segments, though not restricted to the same, include market entry strategies, market size estimations, market trend analysis, market opportunity analysis, market threat analysis, market growth/fall forecasting, primary interviews, secondary research & consumer surveys.
Growth Market Reports
Phone: +1 909 414 1393
Email: [email protected]
Follow Us: LinkedIn | Twitter